Clinical trials: active, in Niger
Mortality, Antimicrobial Resistance
Azithromycin for Child Survival in Niger II
Several randomized controlled trials have demonstrated that azithromycin mass drug administration (MDA) reduces child mortality, but increases antimicrobial resistance (AMR).
- Trial name
- AVENIR II (NCT06358872)
- Testing
- Azithromycin for Oral Suspension
- Where
- Niger
- Volunteers
- 3,300,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria
Integrating the Guardian Spatial Emanator Within AVENIR II
This study will evaluate the implementation of integrating Guardian spatial emanators into the existing AVENIR II azithromycin mass drug administration program in Niger.
- Trial name
- GUARD-AV (NCT07712263)
- Testing
- Spatial Emanator
- Where
- Niger
- Volunteers
- 150,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malnutrition Severe, Vaccination
OptiMAx Will Test Whether SQ-LNS Incentivises Vaccination Uptake in Rural Chad and Niger, With a Cost Effectiveness Analysis. It Will Also Look at Whether Having Received SQ-LNS Before Becoming Malnourished Leads to Better Outcomes for Children Treated Under the OptiMA Protocol.
Malnutrition and infectious disease form a vicious circle, posing a double threat to vulnerable children in low- and middle-income countries.
- Trial name
- OptiMAx (NCT07592260)
- Testing
- small quantity lipid-based supplement (SQ-LNS)
- Where
- 2 sites in Chad, Niger
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Alliance for International Medical Action
Pediatric Cancer
Hospital Based Registry of Childhood Cancer in Pediatric Oncology Units in French Speaking Africa
The ultimate aim of this registry is to collect precise information concerning the children coming to oncology units working with the French African Oncology Group.
- Trial name
- RFAOP (NCT03803735)
- Where
- 14 sites in Burkina Faso, Cameroon and 10 more
- Volunteers
- 10,000 people
- Sponsor
- French Africa Pediatric Oncology Group
Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis
Novel Triple-dose Tuberculosis Retreatment Regimen
To determine if a high-dose first-line regimen is non-inferior (non-inferiority margin 10%) in terms of safety to the same regimen at regular dosing, in previously treated patients with rifampicin-susceptible recurrent…
- Conditions
- Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis, Resistance to Tuberculostatic Drugs
- Trial name
- Tri-Do-Re (NCT04260477)
- Testing
- 6EH³R³Z, 6EHRZ
- Where
- Niger
- Volunteers
- 370 people
- Sponsor
- Institute of Tropical Medicine, Belgium